Is BioInvent International AB (publ) (BOVNF) a Buy, Sell, or Hold?
OTC : BOVNF
BioInvent International AB (publ) — News
$3.2886 USD
$0 (0.0%)
- Volume
- 908
- Average Volume
- 777
- Market Capitalization
- $216.4M
- P/E Ratio
- -4.51
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $4.70
- Year Low
- $3.29
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.32
| Source | Headline |
|---|---|
|
BioInvent International AB (publ) (BOVNF) Discusses Ovarian Cancer Treatment Landscape and TNFR2-Targeted Therapies in Solid Tumors Transcript
BioInvent International AB (publ) (BOVNF) Discusses Ovarian Cancer Treatment Landscape and TNFR2-Targeted Therapies in Solid Tumors Transcript seekingalpha.com - 2026-06-01 21:04:05 |
|
BioInvent to Host Virtual KOL Event to Discuss BI-1808 for the Treatment of Ovarian Cancer, on May 27, 2026
LUND, SE / ACCESS Newswire / May 20, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune‑modulatory antibodies, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, May 27, 2026 at 8:00 AM EDT / 2:00 PM CEST featuring Dmitriy Zamarin MD, PhD (Tisch Cancer Center, Icahn School of Medicine at Mount Sinai), who will join company management to discuss the unmet need and current treatment landscape for ovarian cancer. To register, click here. accessnewswire.com - 2026-05-20 05:50:00 |
